GLP-1-based Therapy and Hair Loss

A More Complicated Story than Telogen Effluvium

Hair loss associated with glucagon-like peptide-1 (GLP-1)–based therapy has become a frequent headline and increasingly a concern raised in dermatology offices. Some patients are worried enough about thinning that they hesitate to start or continue medications that may substantially improve their metabolic and cardiovascular health. That concern is not unfounded: a 2026 TriNetX cohort study of nearly 550,000 matched adults found that GLP-1 receptor agonist (GLP-1 RA) use was independently associated with increased risk of nonscarring alopecia, including telogen effluvium (TE) and androgenetic alopecia (AGA), with risk rising further at 12 months.1

A recent systematic review similarly found that semaglutide and tirzepatide, the agents associated with the greatest magnitude of weight loss, carry the highest reported incidence of hair shedding.2 Rapid weight loss, reduced caloric and protein intake, micronutrient deficiency, and the physiologic stress of substantial weight change are all plausible contributors.

However, the relationship between incretin therapy and hair is not uniformly negative. My colleagues and I reported a 57-year-old man with insulin resistance and AGA who experienced significant improvement in hair density within 6 months of tirzepatide monotherapy, with further improvement at 1 year, in the absence of any other hair-growth treatment.3 Subsequent case reports and reviews have described similar findings, and some authors have proposed that improving insulin sensitivity and scalp perfusion may benefit hair in a subset of patients even as the weight-loss process itself increases shedding in others.^2,4 This makes biologic sense: insulin resistance and metabolic syndrome are linked to endothelial dysfunction, altered microvascular perfusion, chronic inflammation, and hormonal derangement, all of which are plausibly relevant to follicular health. An early-onset AGA case-control study found insulin resistance in 18% of affected men versus 4% of controls, and AGA has long been recognized as a possible cutaneous marker of insulin resistance.^5,6 Correcting the underlying metabolic environment may help hair in some patients even while precipitating TE in others.

This distinction matters because the drug class is not shrinking. Morgan Stanley Research now projects that GLP-1-based therapy among US adults will roughly quadruple over the next decade, from about 13 million users in 2025 to approximately 55 million by 2035.7 Beyond obesity and type 2 diabetes, incretin-based therapies are under investigation for indications reaching well outside metabolic disease. Dermatology will not sit on the sidelines: early evidence suggests a possible role for GLP-1 RAs in psoriasis and hidradenitis suppurativa, largely through anti-inflammatory and weight-related mechanisms, though this remains investigational and is not an approved indication.^8,9

Given the mechanistic overlap between insulin resistance, hyperandrogenism, and conditions like polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS), acne, hirsutism, and AGA, treating a cutaneous manifestation of metabolic disease without addressing the underlying dysfunction may increasingly be viewed as incomplete therapy.¹⁰

PRECAUTIONS FOR PATIENTS INITIATING 
GLP-1-BASED THERAPY

When initiating GLP-1-based therapy in a patient worried about hair loss, nutrition deserves discussion before shedding begins. Excessively rapid weight loss and severe caloric restriction should be avoided when possible. Protein intake is particularly important because inadequate protein during active weight reduction may contribute to shedding as well as to loss of lean mass; expert reviews suggest targets of roughly 1.2 to 1.6 g/kg/day during active weight loss, individualized for body composition, kidney function, age, and comorbidities.¹¹ Because GLP-1 therapy can dramatically reduce appetite and overall intake, patients eating substantially less may fall short on micronutrients even on a previously adequate diet; a nutrient-dense diet and, when adequacy is uncertain, a standard multivitamin are reasonable. Laboratory testing should be individualized rather than reflexive: in patients with substantial shedding, restrictive intake, heavy menstrual bleeding, or other risk factors, I typically consider complete blood count (CBC), ferritin and iron studies, thyroid-stimulating hormone (TSH), vitamin B12, vitamin D, zinc, and folate. For patients delaying therapy specifically over hair-loss concerns, baseline testing of these labs alongside hormonal studies (free and total testosterone, DHEAS, prolactin) can be useful for later comparison.

Timing creates a diagnostic trap of its own. A perimenopausal woman may start a GLP-1-related therapy, lose substantial weight, reduce her intake, and become iron deficient from heavy menses, all while her ovarian estrogen output is independently declining, because estrogen supports the anagen phase and its withdrawal shortens the hair cycle. Attributing all of her shedding to the medication oversimplifies the biology. TE can also unmask previously subtle AGA; the dermatologist’s task is to distinguish acute TE, underlying patterned hair loss, nutritional deficiency, and thyroid or hormonal change, which frequently coexist. GLP-1 RA use has been associated with reductions in serum TSH independent of thyroid hormone changes, likely mediated through weight loss, so thyroid labs and levothyroxine dosing may warrant reassessment after substantial weight change.¹²

Men deserve particular attention. Obesity-associated hypogonadism is common, and substantial weight loss can raise testosterone. Whether this contributes to acceleration or unmasking of genetically determined AGA during incretin therapy has not been established, but it is biologically plausible and merits investigation rather than assumption.

REACTING TO SHEDDING

When a patient presents with shedding months into GLP-1-based therapy, I start with three questions: how quickly is the weight coming off, what is the patient actually eating, and is this truly isolated TE? Correct identifiable deficiencies, moderate excessive caloric restriction, and look carefully for patterned miniaturization. If shedding persists despite correcting these triggers, or if AGA is present, treat the hair disease rather than reflexively stopping a metabolically beneficial medication: minoxidil remains foundational, antiandrogen therapy can be considered in appropriate women with hyperandrogenism, and 5-alpha-reductase inhibitors remain an option for men with AGA and normal testosterone.

UNDERSTAND THE SCIENCE

GLP-1–associated hair loss is real, but “GLP-1s cause hair loss” is an incomplete story. As incretin therapy expands across medicine, dermatologists should be prepared not only to manage its adverse effects but to understand, and in some patients potentially harness, its dermatologic benefits.

“

Because GLP-1 therapy can dramatically reduce appetite and overall intake, patients eating substantially less may fall short on micronutrients even on a previously 
adequate diet; a nutrient-dense diet and, 
when adequacy is uncertain, a standard multivitamin are reasonable.

”